期刊文献+

肾病综合征患者停用糖皮质激素后骨质疏松恢复情况 被引量:1

Amelioration of osteoporosis after glucocorticoid withdrawal in patients with nephrotic syndrome
下载PDF
导出
摘要 目的了解肾病综合征患者停用糖皮质激素(glucocorticoid,GC)后的骨质疏松恢复情况。方法应用双能X线骨密度仪(DEXA)检测79例肾病综合征患者停用糖皮质激素1年后腰椎和股骨颈骨密度情况,记录患者的年龄、性别、体重指数、吸烟史、应用糖皮质激素的时间和累积剂量;分析影响骨质变化的因素。结果79例患者中骨密度正常者占61%,骨量减少者占39%。应用糖皮质激素时间越长的患者骨质恢复相对较慢。结论肾病综合征患者停用激素1年后骨密度可以恢复,且应用激素时间短者恢复快。 [ Objective] To investigate the state of bone mineral density (BMD) after stopping glucocorticoid treatment in patients with nephritic syndrome, and analyze the factors influencing the BMD. [Methods] 79 patients with nephritic syndrome after stopping glucocortieoid therapy (one year later) were observed. BMD in the lumbar spine and the femoral neck were measured by dual-energy X-ray absorptiometry (DEXA). Age, sex, body-mass-index, smoking history, the time and accumulative dose of glucocorticoid were recorded, the factors that influence the BMD were analyzed. [Results] 79 patients were included in this study. Among them, normal BMD and osteopenia were found in 48 (61%) and 31(39%) patients respectively. The speed of removing nomal BMD with receving longer time glucoeorticoid treatment is significant slower compared with receving shorter time glueocorticoid treatment. [ Conclusion] BMD in patients with nephritic syndrome after stopping glueocorficoid therapy (one year later) could be removed, the shorter the patients reeeved glucocorticoid therapy, the faster the BMD reeoved.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2009年第19期2989-2990,2994,共3页 China Journal of Modern Medicine
基金 河北大学附属医院博士基金课题(No:2005011)
关键词 肾病综合征 糖皮质激素 骨密度 恢复 nephritic syndrome glucocortieoid treatment bone mineral density remove
  • 相关文献

参考文献10

  • 1LEONARD MB, FELDMAN HI, SHULTS J, et al. Long-tcrrm, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephritic syndrome [J]. N Engl J Med, 2004, 351: 868-875.
  • 2GULATI S, GODBOLE M, SINGH U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease [J]. Am J Kidney Dis, 2003, 41: 1163-1169.
  • 3陈航,王梅.原发性肾小球疾病应用糖皮质激素患者骨密度情况及骨质疏松预防现状[J].中华肾脏病杂志,2005,21(11):695-696. 被引量:6
  • 4VANSTAA TP, LEUFKENS HGM, COOPER C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis [J]. Osteoporos Int, 2002, 13: 777-787.
  • 5MANNING PJ, EVANS MC, REID IR. Normal bone mineral density following cure of Cushing's syndrome [J]. Clin Endocrinol, 1992, 36: 229-934.
  • 6LODDENKEMPER K, GRAUER A, BURMESTER GR, et al. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases[J]. Clin Exp Rheumatol, 2003, 21: 19-26.
  • 7SAMBROOK PN, KOTOWICZ M, NASH P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of ealcitriol, vitamin D plus calcium, and alendronate plus calcium[J]. J Bone Miner Res, 2003, 18: 919-924.
  • 8DE NIJS RN, JACOBS JWG, ALGRA A, et al. Prevention and treatment of glucocortieoid-induced osteoporosis with active vitamin D3 analogues: a review with recta-analysis of randomized controlled trials including organ transplantation studies [J]. Osteoporos Int, 2004, 15: 589-602.
  • 9STEINBUCH M, YOUKET TE, COHEN S. Oral glucocorticoid ude is associated with an increased risk of fracture[J]. Osteoporos Int, 2004, 15:323-328.
  • 10陈航,王梅.原发性肾小球疾病糖皮质激素性骨质疏松预防治疗的临床研究[J].中华医学杂志,2005,85(31):2207-2210. 被引量:6

二级参考文献24

  • 1Van Stan TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res,2000, 15:993-1000.
  • 2Fujita T, Satomura A, Hidaka M, et al. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephritic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Calcif Tissue Int, 2000,66:195-199.
  • 3Bamsey-Goldman R, Dunn JE, Huang C-F, et aL Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum,1999,42:882-890.
  • 4Naganathan V, Jones G, Nash P, et al. Vertebral fracture risk with long-term corticosteroid therapy: Prevalence and relation to age,bone density, and corticosteroid use. Arvh Intern Med, 2000,160 :2917-2922.
  • 5Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int, 2004,15 : 323 -328.
  • 6Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease ? Am J Kidney Dis, 2003,41 : 1163-1169.
  • 7Eastell R, Reid DM, Compston J, et al. AUK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Int Med, 1998,244:271-292.
  • 8de Nijs RN, Jacobs JWG, Algra A, et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues : a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int, 2004, 15:589-602.
  • 9American College of Rheumatology Ad Hoc Committee on Glueocortieoid-lndueed Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update. Arthritis Rheum, 2001,44 : 1496-1503.
  • 10Geusens P, Dequeker J, Nijs J,et al. Prevention and treatment of osteopenia in the ovariectomized rat : effect of combined therapy with estrogens, 1-alpha vitamin D, and prednisolone. Calcif Tissue Int,1991,48 : 127-137.

共引文献10

同被引文献17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部